We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EVALUATE THE EFFECTIVENESS OF THE RISK MALIGNANCY INDEX (RMI) IN BOTH PREMENOPAUSAL & POSTMENOPAUSAL WOMEN WITH OVARIAN TUMOR.
- Authors
Al-Sultany, Batool abd-Zaid
- Abstract
Objective To evaluate the effectiveness of a risk malignancy index (RMI) in both premenopausal and postmenopausal women with ovarian tumor. Study design Prospective observational study between October 2017 and October 2018. Setting Department of obstetrics and gynecology, Baghdad teaching hospital. Patients and methods Fifty-two women with ovarian mass enrolled in the study Preoperative serum CA125 level, ultrasound findings and menopausal status were recorded to calculate the risk malignancy index (RMI) accounting for each patient. Laparotomy done for each patient and histopathological result were recorded. Results From the Fifty-two women, 71.2% were premenopausal and 28.8% were postmenopausal, twenty-two women (42.3%) had malignant ovarian tumors and 65% of malignant cases were postmenopausal. CA125 concentration was more significant among postmenopausal women than premenopausal (median 152IU/ml versus 32 IU/ml) respectively. Risk malignancy index (RMI) score yielded better diagnostic performance for ovarian masses differentiation than individual parameter. The optimal RMI score to predict malignancy was at a cut-off value of 209 with a sensitivity of 72.7 % and a specificity of 100%. The ROC (receiver operating characteristic) curve for the RMI score was 0.97, which greater than the areas for U/S (0.94) and CA125 (0.84). Conclusion Risk malignancy index (RMI) is a simple diagnostic tool provides a quantitative assessment of risk of malignancy by incorporating serum CA125 levels, U/S findings and menopausal status (in both pre menopause and post menopause) performed individually in women with ovarian masses. The main purpose of this study was the evaluation of the risk of malignancy index defined in a selected population with ovarian tumor. It can be used to discriminate between benign and malignant ovarian tumors. It is useful in referring patients with advanced tumors to a more complex health care unite, although it does not seem to show prognostic value. This index is a simple score system which can be applied directly to clinical practice and might be of value in the preoperative assessment of the ovarian mass with only a few numbers of false negative cases.
- Subjects
BAGHDAD (Iraq); POSTMENOPAUSE; OVARIAN tumors; PREMATURE menopause; CANCER; RECEIVER operating characteristic curves; RISK assessment
- Publication
Karbala Journal of Pharmaceutical Sciences, 2020, Issue 17, p57
- ISSN
7027-2221
- Publication type
Article